JP2009512626A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512626A5 JP2009512626A5 JP2008529690A JP2008529690A JP2009512626A5 JP 2009512626 A5 JP2009512626 A5 JP 2009512626A5 JP 2008529690 A JP2008529690 A JP 2008529690A JP 2008529690 A JP2008529690 A JP 2008529690A JP 2009512626 A5 JP2009512626 A5 JP 2009512626A5
- Authority
- JP
- Japan
- Prior art keywords
- amd
- polymorphism
- preparation according
- identified
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010064930 age-related macular degeneration Diseases 0.000 claims 51
- 208000002780 macular degeneration Diseases 0.000 claims 51
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 230000003449 preventive effect Effects 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 12
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- 235000021466 carotenoid Nutrition 0.000 claims 6
- 150000001747 carotenoids Chemical class 0.000 claims 6
- 238000011161 development Methods 0.000 claims 6
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 6
- 229960005375 lutein Drugs 0.000 claims 6
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 4
- 235000012680 lutein Nutrition 0.000 claims 4
- 239000001656 lutein Substances 0.000 claims 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 4
- 235000010930 zeaxanthin Nutrition 0.000 claims 4
- 239000001775 zeaxanthin Substances 0.000 claims 4
- 229940043269 zeaxanthin Drugs 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 3
- 229930003268 Vitamin C Natural products 0.000 claims 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 3
- 235000013734 beta-carotene Nutrition 0.000 claims 3
- 239000011648 beta-carotene Substances 0.000 claims 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 3
- 229960002747 betacarotene Drugs 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 235000019154 vitamin C Nutrition 0.000 claims 3
- 239000011718 vitamin C Substances 0.000 claims 3
- 239000011701 zinc Substances 0.000 claims 3
- 229910052725 zinc Inorganic materials 0.000 claims 3
- 235000016804 zinc Nutrition 0.000 claims 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 3
- 102100029470 Apolipoprotein E Human genes 0.000 claims 2
- 101710095339 Apolipoprotein E Proteins 0.000 claims 2
- 108010078239 Chemokine CX3CL1 Proteins 0.000 claims 2
- 102000014464 Chemokine CX3CL1 Human genes 0.000 claims 2
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 claims 2
- 108020005067 RNA Splice Sites Proteins 0.000 claims 2
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 238000011331 genomic analysis Methods 0.000 claims 2
- 230000002440 hepatic effect Effects 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 235000008210 xanthophylls Nutrition 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 1
- 101150092476 ABCA1 gene Proteins 0.000 claims 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 108091092878 Microsatellite Proteins 0.000 claims 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 claims 1
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims 1
- 101150079992 Timp3 gene Proteins 0.000 claims 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 108700009124 Transcription Initiation Site Proteins 0.000 claims 1
- 102220346623 c.215T>C Human genes 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229940108928 copper Drugs 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 102200143853 rs111033578 Human genes 0.000 claims 1
- 102200089545 rs662 Human genes 0.000 claims 1
- 230000037436 splice-site mutation Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Claims (23)
- 有効量のカロテノイド及び/又はビタミンC、ビタミンE;βカロチン、亜鉛及び/又は銅、及び/又はそれらの混合物(AREDS Cocktail)からなる、AMD発症の個別リスクが同定された対象用、加齢性黄斑変性症(AMD)予防製剤。
- 前記AMD発症の個別リスクが同定された対象が、ゲノム解析又は黄斑色素の光学濃度の計測のいずれかによりAMD発症の個別リスクが同定された対象である、請求項1に記載のAMD予防製剤。
- 前記カロテノイドがルテイン及び/又はゼアキサンチンである、請求項1又は2に記載のAMD予防製剤。
- 前記AMD発症の個別リスクが同定された対象が、血漿及び/又は皮膚中のキサントフィル及び/又はカロテノイドレベルの測定によりAMD発症の個別リスクが同定された対象である、請求項1〜3のいずれか一項に記載のAMD予防製剤。
- 前記AMD発症の個別リスクが同定された対象が、前記ゲノム解析が実行されることによりAMD発症に関するタンパク質をコードする遺伝子の多型が同定され、AMD発症の個別リスクが同定された対象である、請求項2〜4のいずれか一項に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質が補体H因子である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質がAlu反復欠失アンジオテンシン変換酵素である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、Ser163Argの短鎖コラーゲンCTRP−5コード遺伝子における多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、ABCRコード遺伝子における突然変異ABCA4及びABCA1の多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、パラオキソナーゼ(PON)遺伝子型Gln192Arg及び/又はMet54Leuアポリポタンパク質E(APOE)変異ε2対立遺伝子及びε4対立遺伝子エクソン3における色素上皮由来因子(PEDF)対立遺伝子Met72Thrの多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、CX3CR1(ケモカイン、CX3CL1)受容体SNPであるV249I及びT280Mの多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、Toll様受容体4変異D299Gの多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、肝性リパーゼ−514C−>T及び肝性リパーゼ−480C−−>Tの多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、血管内皮増殖因子(VEGF)のVEGF上流プロモーター/リーダー配列における多型SNP−2578C/A、−1154G/A及び−1154G/G、及び−634G/C(以前は転写開始部位に対する位置から+405C/Gと表記された)並びに−634C/C、及びVEGF5’非翻訳領域多型−460C/Tの多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、MMP−9マイクロサテライト(CA(13−17))多型、すなわち22個以上のCA反復を有する多型である、請求項5に記載のAMD予防製剤。
- 前記AMD発症に関するタンパク質をコードする遺伝子の多型が、TIMP3遺伝子における3’スプライス部位変異、つまりスプライス受容部位内でコンセンサス配列CAGをCAAGに変換するイントロン4/エクソン5接合部における一塩基挿入の多型である、請求項5に記載のAMD予防製剤。
- 前記カロテノイドがキサントフィルを含む、請求項1〜16のいずれか一項に記載のAMD予防製剤。
- 1日当たり0.001〜20mg/kg体重のカロテノイドが前記対象に投与されるように用いられることを特徴とする、請求項1〜17のいずれか一項に記載のAMD予防製剤。
- 1日当たり、0.001〜20mg/kg体重のルテイン及び/又はゼアキサンチン、1〜10mg/kg体重のビタミンC、0.1〜0.3mg/kg体重のβカロチン、1〜10IU/kg体重のビタミンE、0.1〜1.5mg/kg体重の亜鉛及び0.01〜0.05mg/kg体重の銅が前記対象に投与されるように用いられることを特徴とする、請求項1〜18のいずれか一項に記載のAMD予防製剤。
- AMDの発症リスクがあると同定された対象用加齢性黄斑変性症(AMD)予防製剤の製造における、カロテノイド、及び/又はビタミンC、βカロチン、ビタミンE、亜鉛及び銅の混合物の使用。
- 前期AMDの発症リスクがあると同定された対象用加齢性黄斑変性症(AMD)予防製剤が、請求項2〜17のいずれか一項に記載のAMD予防製剤である、請求項20に記載の使用。
- 前記製剤が、1日体重1kg当たり0.001〜20mgのルテイン及び/又はゼアキサンチンを前記対象に投与するうえで十分な量のルテイン及び/又はゼアキサンチンを含有する、請求項20又は21に記載の使用。
- (a)入力された、個体に存在する1つ又は複数の加齢性黄斑変性症対立遺伝子変異のデータを、加齢性黄斑変性症対立遺伝子変異及び変異に付随する加齢性黄斑変性症罹病性に関する情報を含んでなるコンピュータデータベースと比較する手段、及び
(b)前記比較に基づき前記個体が加齢性黄斑変性症(又は加齢性黄斑変性症関連障害)に対し罹病性を有するかどうかを出力する手段、
としてコンピュータを機能させるためのプログラム。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05019532 | 2005-09-08 | ||
PCT/GB2006/003331 WO2007029008A2 (en) | 2005-09-08 | 2006-09-08 | Method of treatment or prevention of age-related macular degeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009512626A JP2009512626A (ja) | 2009-03-26 |
JP2009512626A5 true JP2009512626A5 (ja) | 2010-05-27 |
Family
ID=35478625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008529690A Withdrawn JP2009512626A (ja) | 2005-09-08 | 2006-09-08 | 加齢性黄斑変性症を処置又は予防する方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20090155381A1 (ja) |
EP (1) | EP1922062A2 (ja) |
JP (1) | JP2009512626A (ja) |
KR (1) | KR20080052657A (ja) |
CN (1) | CN101262855A (ja) |
WO (1) | WO2007029008A2 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
EP1853239A1 (en) * | 2005-02-11 | 2007-11-14 | DSMIP Assets B.V. | Use of zeaxanthin for the treatment of diseases of the peripheral retina |
US8088587B2 (en) | 2005-03-04 | 2012-01-03 | Vanderbilt University | Genetic variants increase the risk of age-related macular degeneration |
AU2006249835B2 (en) | 2005-05-26 | 2011-09-08 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
JP5250548B2 (ja) | 2006-06-21 | 2013-07-31 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 疾患の治療のための補体h因子の標的化 |
EP1920711A1 (en) * | 2006-11-13 | 2008-05-14 | DSMIP Assets B.V. | Assessment and improvement of visual performance |
JP5872757B2 (ja) | 2007-03-14 | 2016-03-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ヒト化抗b因子抗体 |
WO2008110283A2 (en) * | 2007-03-14 | 2008-09-18 | Dsm Ip Assets B.V. | Method for prevention of age-related macular degeneration (amd) |
CA2688439A1 (en) * | 2007-05-31 | 2008-12-11 | Joseph Weinstock | Treatment of age-related macular degeneration |
US20100143543A1 (en) * | 2007-09-19 | 2010-06-10 | Hans Hitz | Nutritional supplement formulations for inclusion in foods and fortified foods comprising such supplements |
US20090118228A1 (en) * | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
WO2009105757A2 (en) * | 2008-02-21 | 2009-08-27 | Vanderbilt University | Methods and compositions for diagnosis of age-related macular degeneration |
US9066925B2 (en) | 2009-07-02 | 2015-06-30 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
EA201290286A1 (ru) | 2009-11-05 | 2013-01-30 | Алексион Кембридж Корпорейшн | Лечение пароксизмальной ночной гемоглобинурии, гемолитических анемий и патологических состояний с вовлечением внутрисосудистого и внесосудистого гемолиза |
CA2790097A1 (en) * | 2010-03-05 | 2011-09-09 | Ophthalmopharma Ag | Nutraceutical chocolate or compound chocolate product |
WO2011143637A1 (en) | 2010-05-14 | 2011-11-17 | The Regents Of The University Of Colorado, A Body Corporate | Improved complement receptor 2 (cr2) targeting groups |
EA201291328A1 (ru) | 2010-06-22 | 2013-10-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт | АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3 |
ES2754279T3 (es) * | 2011-07-13 | 2020-04-16 | Univ Georgia | Uso de carotenoides de xantofila para mejorar el rendimiento visual y la eficiencia neuronal |
US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
CN103566049B (zh) * | 2012-08-08 | 2017-08-04 | 浙江医药股份有限公司新昌制药厂 | 用于提高眼睛中视黄斑色素密度并预防或治疗年龄相关性视黄斑衰退症的组合物 |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US9896728B2 (en) | 2013-01-29 | 2018-02-20 | Arcticrx Ltd. | Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD) |
KR101497489B1 (ko) * | 2013-02-08 | 2015-03-03 | 건국대학교 산학협력단 | 노인성 황반변성 환자에서 안방수의 프로테오믹 분석방법을 통한 정보제공방법 및 노인성 황반변성 바이오마커 |
WO2015004266A1 (en) * | 2013-07-12 | 2015-01-15 | Novogenia Gmbh | Personalized nutrient compositions and methods for producing these |
US10774288B2 (en) * | 2013-09-18 | 2020-09-15 | The Werc Shop, LLC | Terpene-based compositions, processes, methodologies for creation and products thereby |
CN104195234A (zh) * | 2014-07-29 | 2014-12-10 | 杭州艾迪康医学检验中心有限公司 | 检测cx3cr1基因v249i突变位点的方法和引物 |
EP3265069A4 (en) * | 2015-03-02 | 2018-11-07 | OmniActive Health Technologies Limited | Method for stress management and overall health status improvement and compositions used therein |
CN105069322B (zh) * | 2015-07-24 | 2018-01-12 | 上海尔云信息科技有限公司 | 疾病易感风险预测装置 |
US10426817B2 (en) * | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
CN107519491B (zh) * | 2017-09-04 | 2020-08-25 | 无锡市人民医院 | Copb2抑制剂的用途 |
CA3119891A1 (en) * | 2018-11-14 | 2020-05-22 | Zhuhai Qiwei Bio-Technology Ltd. | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
JP7443361B2 (ja) * | 2018-12-03 | 2024-03-05 | 珠海岐微生物科技有限公司 | 加齢黄斑変性症の治療方法 |
US11600375B2 (en) | 2021-07-30 | 2023-03-07 | Reviv Global Ltd | Genetically personalized food recommendation systems and methods |
US11894121B2 (en) | 2021-08-06 | 2024-02-06 | Reviv Global Ltd | Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218436B1 (en) * | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
AU719671B2 (en) * | 1995-06-07 | 2000-05-18 | Howard Foundation, The | Pharmaceutically active carotenoids |
US6660297B2 (en) * | 2001-03-23 | 2003-12-09 | Bausch & Lomb Incorporated | Nutritional supplement to treat macular degeneration |
DE10141018A1 (de) * | 2001-08-22 | 2003-03-13 | Eth Zuerich Eidgenoessische Te | Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges |
DE60318390T2 (de) * | 2002-01-30 | 2008-12-18 | Dsm Ip Assets B.V. | Lutein/zeaxanthin gegen blendung |
DE20320101U1 (de) * | 2003-12-23 | 2004-04-29 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Mikronährstoffkombinationsprodukt geeignet zur ergänzenden bilanzierten Diät bei altersbedingter Makuladegeneration |
FR2883182B1 (fr) * | 2005-03-16 | 2008-02-15 | Novartis Ag | Composition de vitamines utiles dans le traitement des maladies oculaires |
-
2006
- 2006-09-08 EP EP06779349A patent/EP1922062A2/en not_active Ceased
- 2006-09-08 US US11/991,400 patent/US20090155381A1/en not_active Abandoned
- 2006-09-08 JP JP2008529690A patent/JP2009512626A/ja not_active Withdrawn
- 2006-09-08 WO PCT/GB2006/003331 patent/WO2007029008A2/en active Application Filing
- 2006-09-08 KR KR1020087008390A patent/KR20080052657A/ko not_active Application Discontinuation
- 2006-09-08 CN CNA2006800331506A patent/CN101262855A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009512626A5 (ja) | ||
Nakanishi et al. | Functional significance of rare neuroligin 1 variants found in autism | |
Murphy et al. | Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G× G and G× E differences in health and disease | |
Arte et al. | Candidate gene analysis of tooth agenesis identifies novel mutations in six genes and suggests significant role for WNT and EDA signaling and allele combinations | |
Watanabe et al. | Fabp7 maps to a quantitative trait locus for a schizophrenia endophenotype | |
Guillot et al. | Lung disease modifier genes in cystic fibrosis | |
Heiman-Patterson et al. | Background and gender effects on survival in the TgN (SOD1-G93A) 1Gur mouse model of ALS | |
Haghverdizadeh et al. | ABCC8 genetic variants and risk of diabetes mellitus | |
Alves-Ferreira et al. | Identification of genetic risk factors for maxillary lateral incisor agenesis | |
Tong et al. | LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis | |
Konjikusic et al. | Mutations in Kinesin family member 6 reveal specific role in ependymal cell ciliogenesis and human neurological development | |
Domschke | Clinical and molecular genetics of psychotic depression | |
Poon et al. | Very important pharmacogene summary for VDR | |
Katsura et al. | WDR72 models of structure and function: A stage-specific regulator of enamel mineralization | |
Heruth et al. | Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model | |
Qiu et al. | Sodium taurocholate cotransporting polypeptide (NTCP) deficiency: Identification of a novel SLC10A1 mutation in two unrelated infants presenting with neonatal indirect hyperbilirubinemia and remarkable hypercholanemia | |
Hloušková et al. | Mutations in AXIN2 gene as a risk factor for tooth agenesis and cancer: A review | |
Andley et al. | Probing the changes in gene expression due to α-crystallin mutations in mouse models of hereditary human cataract | |
Blanco et al. | Not all DMT1 mutations lead to iron overload | |
Pavan et al. | ALDH1A2 (RALDH2) genetic variation in human congenital heart disease | |
Heiman-Patterson et al. | Genetic background effects on disease onset and lifespan of the mutant dynactin p150Glued mouse model of motor neuron disease | |
Škorić-Milosavljević et al. | Common genetic variants contribute to risk of transposition of the great arteries | |
Pepineli et al. | Vitamin D receptor gene polymorphisms are associated with leprosy in Southern Brazil | |
Szczepańska et al. | Involvement of vascular endothelial growth factor-460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis | |
Laugel-Haushalter et al. | Genetic evidence supporting the role of the calcium channel, CACNA1S, in tooth cusp and root patterning |